Glucagon-like peptide-1 agonistsBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.d7282 (Published 11 January 2012) Cite this as: BMJ 2012;344:d7282
- Raj Padwal, associate professor of medicine
- 12F1.26 Walter C Mackenzie Health Sciences Centre, AB, Edmonton, Canada T6G2B7
Over the past century, considerable progress has been made in understanding the role of enteroendocrine signals in regulating glucose. One substantial advance was the delineation of the “the incretin effect,” which refers to the ability of orally administered glucose to stimulate pancreatic insulin secretion to a greater extent than glucose administered intravenously.1 Glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide are the two key enteroendocrine factors responsible for the incretin effect.2 GLP-1, secreted from the lower gastrointestinal tract L-cells after nutrient ingestion, stimulates endogenous insulin secretion in a glucose dependent manner, inhibits postprandial glucagon release, delays gastric emptying, and increases satiety.3 However, GLP-1 is of limited therapeutic use because it is rapidly degraded by dipeptidyl peptidase 4, an enzyme produced at epithelial and endothelial membranes.
In the linked systematic review and meta-analysis (doi:10.1136/bmj.d7771), Vilsbøll and colleagues assess the effect of GLP-1 receptor agonists on weight loss, blood pressure, plasma concentrations of cholesterol and liver enzymes, and glycaemic control.4 The two currently approved GLP-1 analogues, exenatide and liraglutide, mimic the action of GLP-1 but are resistant to the proteolytic …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial